Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront

被引：4
|
作者：
Breccia, Massimo [1 ]
Molica, Matteo [1 ]
Colafigli, Gioia [1 ]
Zacheo, Irene [1 ]
Latagliata, Roberto [1 ]
Tafuri, Agostino [2 ,3 ]
Alimena, Giuliana [1 ]
机构：
[1] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy
[2] S Andrea Hosp, Hematol, Rome, Italy
[3] Univ Roma La Sapienza, Dept Mol Med, Hematol, I-00161 Rome, Italy
来源：
LEUKEMIA & LYMPHOMA | 2015年 / 56卷 / 07期
关键词：
D O I：
10.3109/10428194.2014.993391
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2206 / 2207
页数：2
相关论文
共 50 条
  • [21] Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    Milojkovic, Dragana
    Nicholson, Emma
    Apperley, Jane F.
    Holyoake, Tessa L.
    Shepherd, Pat
    Drummond, Mark W.
    Szydlo, Richard
    Bua, Marco
    Foroni, Letizia
    Reid, Alistair
    Khorashad, Jamshid S.
    de Lavallade, Hugues
    Rezvani, Katy
    Paliompeis, Christos
    Goldman, John M.
    Marin, David
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (02): : 224 - 231
  • [22] Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
    Simone Claudiani
    Farhan Chughtai
    Afzal Khan
    Chloe Hayden
    Fiona Fernando
    Jamshid Khorashad
    Victoria Orovboni
    Glenda Scandura
    Andrew Innes
    Jane F. Apperley
    Dragana Milojkovic
    Leukemia, 2024, 38 : 796 - 802
  • [23] Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
    Claudiani, Simone
    Chughtai, Farhan
    Khan, Afzal
    Hayden, Chloe
    Fernando, Fiona
    Khorashad, Jamshid
    Orovboni, Victoria
    Scandura, Glenda
    Innes, Andrew
    Apperley, Jane F.
    Milojkovic, Dragana
    LEUKEMIA, 2024, 38 (04) : 796 - 802
  • [24] MULTICENTER STUDY OF COMORBIDITY IN CANARIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
    Saez-Perdomo, M.
    Viedma, J.
    Bilbao-Sieyro, C.
    Herranz, N.
    Gonzalez San Miguel, J. D.
    Luzardo, H.
    Brito, G.
    Navarro, N.
    Tapia, M.
    Ruano, A.
    Gomez-Casares, M. T.
    HAEMATOLOGICA, 2015, 100 : 443 - 444
  • [25] Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
    Jabbour, Elias
    Kantarjian, Hagop M.
    O'Brien, Susan
    Shan, Jianqin
    Quintas-Cardama, Alfonso
    Garcia-Manero, Guillermo
    Rios, Mary Beth
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4260 - 4265
  • [26] Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
    Milojkovic, Dragana
    Apperley, Jane
    CLINICAL CANCER RESEARCH, 2009, 15 (24) : 7519 - 7527
  • [27] Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
    Yang, Sen
    Zhang, Xiaoshuai
    Gale, Robert Peter
    Du, Xin
    Chen, Chun-yan
    Weng, Jian-yu
    Huang, Jian
    Li, Fei
    Zeng, Yun
    Xiao, Zhen
    Hu, Jian-da
    Yang, Li-jie
    Liu, Zhuo-gang
    Li, Guo-hui
    Sun, Xiu-li
    Yang, Wei
    Feng, Ru
    Han, Yan-qiu
    Jing, Yu
    Xu, Na
    Liu, Xiao-li
    Liu, Zhen-fang
    Wang, Xiao-dong
    Wu, Shi-xin
    Liang, Rong
    Zhang, Yan-li
    Yang, Yun-fan
    Zhu, Huan-ling
    Pan, Ling
    Meng, Li
    Zhao, Yan-hong
    Yi, Hai
    Liu, Yi-lan
    Zhang, Wei-hua
    Zheng, Yuan-jun
    Zhou, Ze-ping
    Chen, Su-ning
    Qiu, Hui-ying
    Li, Wei-ming
    Jia, Zhi-lin
    Bai, Yan-liang
    Lin, Li-e
    Liu, Bing-cheng
    Liu, Chun-shui
    Luo, Jian-min
    Meng, Jun-xia
    Sun, Zhi-qiang
    Zhang, Yan-qing
    Huang, Xiao-jun
    Jiang, Qian
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (07) : E183 - E186
  • [28] Expert opinion—management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors
    Andreas Hochhaus
    Massimo Breccia
    Giuseppe Saglio
    Valentín García-Gutiérrez
    Delphine Réa
    Jeroen Janssen
    Jane Apperley
    Leukemia, 2020, 34 : 1495 - 1502
  • [29] Impact of Prior Second-Generation Tyrosine Kinase Inhibitors on the Outcome of Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia.
    Benedicte, Deau
    Emmanuel, Bachy
    Nicole, Raus
    Franck-emmanuel, Nicolini
    Delphine, Rea
    Oumedaly, Reman
    Natacha, Maillard
    Ame, Shanti
    Nathalie, Fegueux
    Valerie, Coiteux
    Martine, Gardembas
    Aude, Charbonnier
    Anne, Huyn
    Yves, Cahn Jean
    Agnes, Buzyn
    BLOOD, 2010, 116 (21) : 933 - 933
  • [30] The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors
    Haznedaroglu, Ibrahim C.
    Cetiner, Mustafa
    Ilhan, Osman
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (02): : 1 - 3
12345